See All Slides - tctmd.com

Slides

Presentation TCT 2017

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

Presenter: Azeem Latib, Dean J. Kereiakes

October 31, 2017

Presentation TCT 2017

In Which Direction is Cell Based Heart Failure Therapy Headed?

Presenter: Francisco Fdez-Aviles, Emerson C. Perin

October 31, 2017

Presentation TCT 2017

How to Align Incentives in the Cath Lab

Presenter: Peter L Duffy, Hadley Wilson, Herbert D. Aronow

October 31, 2017

Presentation TCT 2017

FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices

Presenter: Martin B. Leon, Changfu Wu, John C Laschinger

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Master Perspectives: Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement?

Presenter: Barry D. Rutherford, Robert W. Yeh

October 31, 2017

Presentation TCT 2017

Transpericardial Access for LAA Closure

Presenter: Stefan C. Bertog, Apostolos Tzikas, Krzysztof Bartus

October 31, 2017

Presentation TCT 2017

Insights From the PLATINUM DIVERSITY Study

Presenter: Alice K. Jacobs, Spencer B. King III, Wayne B. Batchelor

October 31, 2017

Presentation TCT 2017

Building the CHIP Heart Team: Institutional and Network Strategies for a Successful CHIP Program

Presenter: Farouc Jaffer, Ajay J. Kirtane, Nicholas J. Lembo

October 31, 2017

Presentation TCT 2017

Case Presentation: No Reflow After Primary PCI

Presenter: David P. Faxon, Robert S. Schwartz, Mohamed Abdel-Wahab

October 31, 2017

Advertisement

Slides

ABSORB IV 30-Day Results: Is Improved Technique Reflected in Superior Early Outcomes?

In Which Direction is Cell Based Heart Failure Therapy Headed?

How to Align Incentives in the Cath Lab

FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Master Perspectives: Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement?

Transpericardial Access for LAA Closure

Insights From the PLATINUM DIVERSITY Study

Building the CHIP Heart Team: Institutional and Network Strategies for a Successful CHIP Program

Case Presentation: No Reflow After Primary PCI

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content